Information Provided By: 
Fly News Breaks for January 9, 2020
HALO
Jan 9, 2020 | 05:18 EDT
BMO Capital analyst Do Kim upgraded Halozyme Therapeutics to Outperform from Market Perform with a price target of $24, up from $17. The analyst expectx Darzalex and Perjeta/Herceptin approvals to help reverse the company's declining royalty revenues and return it to growth. In addition, the immediate restructuring after the PEGPH20 failure and prioritizing the "reliable" Enhanze business enable near-term profitability and sustainable positive cash flow, Kim tells investors in a research note.
News For HALO From the Last 2 Days
There are no results for your query HALO
